Burning Rock Biotech Ltd. ADR (BNR) News
Filter BNR News Items
BNR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BNR News Highlights
- For BNR, its 30 day story count is now at 3.
- Over the past 7 days, the trend for BNR's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- ROCK, LUNG and CELL are the most mentioned tickers in articles about BNR.
Latest BNR News From Around the Web
Below are the latest news stories about BURNING ROCK BIOTECH LTD that investors may wish to consider to help them evaluate BNR as an investment opportunity.
Burning Rock's minimal residual disease (MRD) product supports advancement in early-stage non-small cell lung cancer treatment, with results published in the Cancer CellGUANGZHOU, China, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) is delighted to announce that our personalized Minimal Residual Disease (MRD) product, CanCatch® (PROPHETTM panel), was enrolled in a prospective observational study (MEDAL, MEthylation based Dynamic Analysis for Lung cancer, NCT03634826). The MEDAL is a 5-year study that aimed to investigate the clinical utility of MRD in patients with non-small cell lung |
Burning Rock Biotech Limited (NASDAQ:BNR) Q2 2023 Earnings Call TranscriptBurning Rock Biotech Limited (NASDAQ:BNR) Q2 2023 Earnings Call Transcript August 31, 2023 Operator: Good morning, ladies and gentlemen. Thank you for standing by. Welcome to Burning Rock’s 2023 Second Quarter Earnings Conference Call. [Operator Instructions] Please note that today’s conference is being recorded. Before we begin, I’d like to remind you that this conference […] |
Q2 2023 Burning Rock Biotech Ltd Earnings CallQ2 2023 Burning Rock Biotech Ltd Earnings Call |
Burning Rock Reports Second Quarter 2023 Financial ResultsGUANGZHOU, China, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended June 30, 2023. Recent Business Updates Therapy Selection and Minimal Residual Disease (MRD) Presented study results on extensive-stage small-cell lung cancer and ovarian cancer a |
Is Burning Rock Biotech (NASDAQ:BNR) In A Good Position To Deliver On Growth Plans?We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining... |
Burning Rock Provides Second Quarter 2023 Business Updates and Schedules Earnings Release on August 31, 2023GUANGZHOU, China, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the second quarter of 2023 before the U.S. market opens on August 31, 2023. Following the release, company management will host a conference call at 8:00 a.m. ET |
Burning Rock Announces Resignation and Appointment of DirectorsGUANGZHOU, China, June 28, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced the resignation of Dr. Shaokun (Shannon) Chuai as a director from the board of directors of the Company (the “Board”) and as the Company’s Chief Scientific Officer, effective June 30, 2023. Dr. Shaokun (Shannon) Chuai will |
A Look At The Fair Value Of Burning Rock Biotech Limited (NASDAQ:BNR)Key Insights Using the 2 Stage Free Cash Flow to Equity, Burning Rock Biotech fair value estimate is US$1.94 Burning... |
Burning Rock's precision oncology diagnostics product supports advancement in late-stage breast cancer treatment, with results published in the New England Journal of MedicineGUANGZHOU, China, June 08, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) is pleased to announce that our flagship comprehensive genomic profiling (CGP) product, OncoScreenTM Plus, was featured in a phase 3 multi-regional clinical trial (MRCT), along with FoundationOneCDx, in support of advancement in breast cancer treatment. The study, CAPItello-291, sponsored by our pharma client AstraZeneca, is a phase 3 trial that assessed th |
Burning Rock Biotech Limited (NASDAQ:BNR) Q1 2023 Earnings Call TranscriptBurning Rock Biotech Limited (NASDAQ:BNR) Q1 2023 Earnings Call Transcript May 30, 2023 Burning Rock Biotech Limited misses on earnings expectations. Reported EPS is $-0.39 EPS, expectations were $0.2. Operator: Good day, and thank you, for standing by. Welcome to the Burning Rock’s 2023 Q1 Earnings Conference Call. Before we begin, I’d like to remind […] |